Recordati to meet with the financial community and specialized press in Milan

Milan, 11 December 2008 – Recordati S.p.A. will be hosting a meeting with the financial community and specialized press on:

Thursday 18 December 2008 at 4 pm
Palazzo Mezzanotte
Piazza degli Affari, 6 – Milan

At the meeting Recordati’s 2009-2011 Business Plan will be presented and the Group’s development strategy and objectives for this period will be discussed.

A simultaneous translation into English of the proceedings will be available via conference call. Dial-in numbers and access ID are:

Italy  +39 02 36005955
UK   +44 (0) 1452587427
USA   +18665516755
France   +33 (0) 170751217
Germany  +49 (0) 6922227071

ID to access the call in the English language: 76990843

Callers are invited to dial-in 10 minutes before conference time.   A recording of the conference call will be subsequently placed on the website:
http://www.recordati.com/rec_en/investors/presentations/

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,400, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the emerging markets of Eastern Europe.  A European field force of over 1,300 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati’s current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations.  Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company’s leading product.  Consolidated revenue for 2007 was € 628.4 million, operating income was € 131.5 million and net income was € 84.9 million.

For further information:

Recordati website:  www.recordati.com